Innovative Clinical Trial for Nantheia™ ATL5 Targets Addiction Relief
Exciting Clinical Trial Launch for Nantheia™ ATL5
ANANDA Scientific Inc., a dynamic biopharmaceutical company, has initiated a groundbreaking clinical trial aimed at exploring the potential benefits of Nantheia™ ATL5. This investigational drug leverages cannabidiol (CBD) integrated with ANANDA’s proprietary delivery technology, which is designed to work alongside delta-9-tetrahydrocannabinol (THC). The trial focuses on individuals grappling with co-occurring conditions of opioid use disorder (OUD) and chronic pain, reflecting a pivotal moment in the pursuit of effective treatment solutions.
Clinical Trial Overview and Objectives
The clinical trial will take place at an esteemed medical institution, with leadership from the renowned Dr. Joao P. De Aquino, M.D. Dr. Aquino is the Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory at the Yale School of Medicine. The research is funded by a generous grant from the National Institute on Drug Abuse (NIDA), highlighting the significant commitment to tackling these pressing health issues.
Primary and Secondary Objectives
The primary goal of the clinical trial is to assess the therapeutic effectiveness of Nantheia™ ATL5, administered with THC, to alleviate pain and mitigate cue-induced cravings in individuals diagnosed with OUD and chronic pain. The secondary goal aims to investigate whether the inclusion of THC alters the effects of Nantheia™ ATL5 on its own.
Study Design
This study will follow a randomized, double-blind, placebo-controlled, crossover design, ensuring rigorous evaluation. Participants who are stabilized on consistent doses of methadone will be randomly assigned to receive a single dose of Nantheia™ ATL5 (200 mg or 400 mg) alongside THC (5 mg, 10 mg, or placebo). This design aims to yield reliable outcomes that can influence future therapeutic strategies.
Collaborative Efforts and Expectations
Dr. De Aquino expressed enthusiasm about partnering with ANANDA on this important research initiative. He noted, “We are excited to collaborate with ANANDA to get this trial underway. Understanding how CBD, co-administered with low doses of THC, may work together to benefit patients with OUD and chronic pain could lead to significant advancements in treating these debilitating conditions.”
ANANDA's CEO, Sohail R. Zaidi, also conveyed optimism regarding the trial. He emphasized the importance of this clinical research in developing non-addictive treatments for opioid addiction, an area where there is a substantial unmet medical need.
Deep Dive into Nantheia™ ATL5
Nantheia™ ATL5 is noteworthy as it combines CBD with ANANDA’s innovative Liquid Structure™ delivery technology, which enhances absorption and stability. Early studies suggest that this delivery technology could significantly improve the effectiveness of cannabinoid treatments, making it a promising candidate for therapeutic use in various conditions.
Company Commitment to Innovation
ANANDA Scientific remains committed to pioneering research that transforms neuropsychiatric health. The company is dedicated to developing medications that not only address conditions such as PTSD, pain, anxiety and OUD but also facilitate smoking cessation. With a focus on creating bioavailable, water-soluble, and shelf-stable cannabinoid products, ANANDA is proactively shaping the future of treatment in its field.
Conclusion and Future Directions
The commencement of this clinical trial represents a significant stride towards understanding the potential synergy between CBD and THC in alleviating the dual challenges posed by opioid use disorder and chronic pain. As the trial progresses, the medical community and stakeholders will be closely observing the outcomes, hoping to uncover new avenues for therapeutic approaches that could benefit countless individuals.
Frequently Asked Questions
What is Nantheia™ ATL5?
Nantheia™ ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure™ delivery technology aimed at treating opioid use disorder and chronic pain.
Who is leading the clinical trial?
The clinical trial is led by Dr. Joao P. De Aquino, M.D., who is affiliated with the Yale School of Medicine.
What are the primary goals of the trial?
The primary objective is to evaluate the therapeutic potential of Nantheia™ ATL5 paired with THC in alleviating pain and reducing cravings in patients with co-occurring conditions.
How will the trial be conducted?
This will be a randomized, double-blind, placebo-controlled, crossover study involving participants stabilized on methadone.
What is ANANDA Scientific's overall mission?
ANANDA Scientific is dedicated to developing life-changing medicines that improve neuropsychiatric health and addresses pressing medical needs through innovative therapeutic solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exploring Innovative Strategies for Insurance Risk Evaluation
- Telenor Group's Q3 2024 Results: Join Us for Insights
- Investors Urged to Act: Class Actions for EXTR, PDD, CXM, SYM
- Bitcoin's Rally Potential: Factors to Watch Before the Election
- Kestra Holdings Partners with Stone Point Capital for Growth
- LeChase Construction Elevates Leadership for Future Growth
- Halper Sadeh LLC Investigates Various Companies for Shareholders
- USPS Gears Up for 2024 Holiday Shipping Rush
- Join the DTA Foundation's Exciting Campaign for Children's Oral Health!
- Walmart's Market Analysis: Insights for Savvy Investors
Recent Articles
- Kioxia Unveils Next-Gen SSD Enhancements at OCP Summit
- Travelers Spend Big This Holiday Season with Elevated Expectations
- Avicena Enhances Leadership with Industry Veteran Greg Dougherty
- DataSnipper Enhances Audit Processes with AI Solutions
- CareDx Reports Promising Financial Results for Recent Quarter
- Big Tech and Banks Drive US Market Records Amid China Woes
- Oppenheimer Welcomes Christian Baetz to Strengthen Banking Team
- FB Financial Corporation Posts Strong Q3 2024 Earnings Report
- NIP Group Expands Portfolio with Young Will Acquisition
- MicroVision Secures $75 Million Funding for Strategic Growth
- Nigeria's Consumer Inflation Soars to 32.70% in September
- Challenges Facing Israel's Economy Amid Ongoing Conflict
- Expanding Horizons: Coldwell Banker's Venture into Africa
- Kremlin Clarifies Saudi Arabia's Role in Upcoming BRICS Summit
- New York Times Takes Action Against Perplexity Over Content Use
- UnitedHealth Surpasses Earnings Expectations with Strong Revenue Results
- Valeo Revolutionizes Dock Operations with Innovative Automation
- Wise's Q2 Update Highlights Strong Customer Growth and Revenue
- Oppenheimer Welcomes Christian Baetz as Managing Director
- Netflix's Future: Overcoming Slower Subscriber Growth Strategies
- Ubiquigent and Alleo Forge Partnership for AI in Drug Discovery
- UnitedHealth's Strong Q3 Earnings Underscore Growth Potential
- Boeing Workers Rally Amid Ongoing Strike and Job Cuts Discussions
- UnitedHealth's Profit Surges Amid Expanding Membership Base
- Experience Luxury with Johnnie Walker and Perfect Moment
- Matt Murphy Takes the Helm as unWired Broadband CEO
- Newmont and MKS PAMP Unveil Innovative Gold Bar for Consumers
- Alimentiv and Satisfai Health Forge New Frontiers in GI Imaging
- Core4ce Expands Operations by Acquiring Azimuth Corporation
- Exciting News from Ituran Location and Control: Q3 2024 Insights
- Joni Eareckson Tada's Inspiring Journey at 75
- Global Growth of Vegetarian Capsules Market to $3.5 Billion
- Exploring the Evolving Landscape of Chemical Feed Systems
- Future of Sustainable Packaging Coatings: Market Insights
- ABC7 and Treasurer Maria Pappas Host Phone Bank for Refunds
- David Raney Joins SunHydrogen Board to Drive Hydrogen Innovation
- Snapdocs Revolutionizes Mortgage Closings with New Features
- BitFuFu's Presence at AIM Summit Dubai 2024 Shines Bright
- Design Pickle Introduces Innovative Automation Features
- NIP Group Expands Horizons with Young Will Acquisition
- Revamping Global Retirement Systems Amidst Changing Demographics
- Immuron's Travelan® Shows Robust Sales Increase in Global Market
- Klotho Neurosciences Welcomes New COO to Propel Innovation
- Innovative Hardening Techniques Transform CNC Turning Capabilities
- Impact BioMedical Secures Canadian Patent for Inflammatory Relief
- Sound Growth Partners Strengthens Portfolio with Stueve
- Global Net Lease to Share Q3 2024 Financial Performance Soon
- WeRide Introduces GXR: The Revolutionary Robotaxi Experience
- Karolinska Development AB Invites Shareholders to EGM
- Excelsior Energy Partners with Proximal for AI-Driven Solutions